Movement disorders clinical practice · 2026
Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jagusch Frank, Redl Elena, Theyer Christoph, Djamshidian Atbin, Fanciulli Alessandra, Poewe Werner, Mahlknecht Philipp, Heim Beatrice, Seppi Klaus, Krismer Florian
Аннотация
BACKGROUND: Reduced cardiac uptake on 123Iodine-metaiodobenzylguanidine (MIBG) scintigraphy is a valuable tool for differentiating neurodegenerative parkinsonism but interpretation can be difficult due to comorbidities and drug-tracer interactions.
OBJECTIVES: This study investigated factors limiting the clinical applicability of MIBG scintigraphy in everyday clinical practice.
METHODS: Patient records (2021-2022) were retrospectively reviewed, independent of whether MIBG scintigraphy was performed, for comorbidities and concomitant medication confounding its interpretation.
RESULTS: Six hundred ninety five patients (640 Parkinson's disease, 22 multiple system atrophy, 33 progressive supranuclear palsy) were included. Factors potentially influencing cardiac MIBG binding were present in 55.3% with 18.1% exhibiting multiple factors. Medications with known drug-tracer interactions were found in 46.9% and comorbidities associated with reduced cardiac MIBG uptake in 20.9%.
CONCLUSIONS: The clinical utility of MIBG scintigraphy is frequently restricted by medications and comorbidities highlighting the need of careful planning in clinical practice.
OBJECTIVES: This study investigated factors limiting the clinical applicability of MIBG scintigraphy in everyday clinical practice.
METHODS: Patient records (2021-2022) were retrospectively reviewed, independent of whether MIBG scintigraphy was performed, for comorbidities and concomitant medication confounding its interpretation.
RESULTS: Six hundred ninety five patients (640 Parkinson's disease, 22 multiple system atrophy, 33 progressive supranuclear palsy) were included. Factors potentially influencing cardiac MIBG binding were present in 55.3% with 18.1% exhibiting multiple factors. Medications with known drug-tracer interactions were found in 46.9% and comorbidities associated with reduced cardiac MIBG uptake in 20.9%.
CONCLUSIONS: The clinical utility of MIBG scintigraphy is frequently restricted by medications and comorbidities highlighting the need of careful planning in clinical practice.